Short Interest in Chimerix Inc (NASDAQ:CMRX) Declines By 11.0%

Chimerix Inc (NASDAQ:CMRX) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 996,600 shares, a drop of 11.0% from the May 30th total of 1,119,700 shares. Based on an average daily trading volume, of 515,700 shares, the days-to-cover ratio is presently 1.9 days. Currently, 2.3% of the company’s shares are sold short.

In other Chimerix news, CEO Michael A. Sherman acquired 30,000 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were purchased at an average cost of $3.48 per share, for a total transaction of $104,400.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Martha J. Demski acquired 18,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was acquired at an average price of $3.60 per share, for a total transaction of $64,800.00. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 78,000 shares of company stock worth $256,800. Corporate insiders own 12.50% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP lifted its stake in shares of Chimerix by 52.9% in the 4th quarter. Two Sigma Investments LP now owns 308,732 shares of the biopharmaceutical company’s stock valued at $793,000 after purchasing an additional 106,750 shares during the period. Rhumbline Advisers lifted its stake in shares of Chimerix by 45.7% in the 4th quarter. Rhumbline Advisers now owns 65,845 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 20,654 shares during the period. Deutsche Bank AG raised its stake in Chimerix by 27.7% during the fourth quarter. Deutsche Bank AG now owns 258,033 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 55,950 shares during the last quarter. Two Sigma Advisers LP raised its stake in Chimerix by 18.1% during the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 20,700 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Chimerix by 2.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,612,871 shares of the biopharmaceutical company’s stock valued at $6,715,000 after buying an additional 56,347 shares during the last quarter. Institutional investors own 69.71% of the company’s stock.

A number of brokerages have recently weighed in on CMRX. Cowen reiterated a “hold” rating on shares of PDL BioPharma in a research report on Thursday, May 9th. Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, ValuEngine lowered WideOpenWest from a “hold” rating to a “sell” rating in a research report on Friday, June 28th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Chimerix currently has an average rating of “Hold” and a consensus target price of $4.75.

Shares of CMRX remained flat at $$3.69 on Friday. The stock had a trading volume of 229,269 shares, compared to its average volume of 335,482. The firm has a market capitalization of $188.46 million, a price-to-earnings ratio of -2.58 and a beta of 1.23. The firm’s 50-day moving average price is $3.62. Chimerix has a 52 week low of $1.74 and a 52 week high of $4.83.

Chimerix (NASDAQ:CMRX) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.35). The company had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.00 million. Chimerix had a negative return on equity of 36.85% and a negative net margin of 757.77%. Analysts forecast that Chimerix will post -1.02 EPS for the current fiscal year.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Read More: What does a hold rating mean?

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.